You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 27, 2024

Claims for Patent: 11,395,818

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,395,818

Title:	Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-- 3-yl)-2-fluorophenyl)-3-phenylurea
Abstract:	Provided herein are low impurity compositions comprising a compound represented by Formula (I): ##STR00001## which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFR.alpha. kinases, and oncogenic forms thereof.
Inventor(s):	Kaufman; Michael D. (Waltham, MA), Bone; Scott (Bend, OR), Bloom; Corey (Bend, OR), Jordan; Fred (Bend, OR)
Assignee:	Deciphera Pharmaceuticals, LLC (Waltham, MA)
Application Number:	17/180,241
Patent Claims:	1. A pharmaceutical solid dispersion composition comprising: a) a solid dispersion comprising: hydroxypropyl methyl cellulose acetate succinate; and 50 mg of an amorphous form of a compound represented by Formula (I) ##STR00045## and b) one or more pharmaceutically acceptable carriers; wherein: a compound represented by Formula (II): ##STR00046## is present in the solid dispersion composition in amount of about 0.1% (w/w) to about 0.5% (w/w) by weight based on the total weight of the solid dispersion composition; and aniline and diphenyl urea are each present in amount equal to or less than about 0.5% by weight based on the total weight of solid dispersion composition. 2. A pharmaceutically acceptable composition for orally delivering 50 mg of a compound represented by Formula (I): ##STR00047## comprising: a) a solid dispersion having: 50 mg of the compound wherein the compound is present in amorphous form; hydroxypropyl methyl cellulose acetate succinate; and b) a pharmaceutically acceptable carrier; wherein a compound represented by Formula (II): ##STR00048## is present in composition in amount equal to or less than about 1.5% by weight based on the total weight of the composition; and aniline is present in the composition in amount equal to or less than about 0.5% by weight based on the total weight of the composition. 3. A pharmaceutically acceptable composition for orally delivering 50 mg of a compound represented by Formula (I): ##STR00049## comprising: a solid dispersion having 50 mg of the compound wherein the compound is present in amorphous form, and hydroxypropyl methyl cellulose acetate succinate; about 25-45% by weight of a bulking agent based on the total amount of the pharmaceutical composition; about 25-45% by weight of a filler based on the total amount of the pharmaceutical composition; and a glidant and/or a lubricant; wherein when exposed to 60% relative humidity at 25.degree. C. for 1 month, the composition has not more than about 0.5% (w/w) of a compound represented by Formula (II): ##STR00050##

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.